Siemens Healthineers Ag · XETR:SHL

Siemens Healthineers — Q2 FY2018 Earnings Presentation

14 slides from Siemens Healthineers's earnings presentation, May 3, 2018

  1. Slide 1: Siemens Healthineers: Shaping the future of healthcare

    Q2 FY2018 Analyst Call Siemens Healthineers: Shaping the future of healthcare Dr. Bernd Montag, CEO | Dr. Jochen Schmitz, CFO May 3, 2018 Page 0 | Unrestricted © Siemens Healthcare GmbH, 2018

  2. Slide 2: Notes and forward looking statements

    Notes and forward looking statements This presentation has been prepared solely for use at this meeting. By attending the meeting where this presentation is made or accessing this presentation, you agree to be bound by the following limitations. This material is given in conjunction with an oral pre

  3. Slide 3: Q2 FY2018 – on track to meet our targets

    Q2 FY2018 – on track to meet our targets • Comparable revenue up by 4% driven by strong Imaging business • Flat topline development at Diagnostics, but good instrument placements point towards better development in H2 2018 • Continue to receive excellent customer feedback on Atellica with 250+ analy

  4. Slide 4: Major innovations across all segments

    Major innovations across all segments MAGNETOM Sola1) ACUSON Juniper Cios Select with FD PCR kit for HPV first 1.5T BioMatrix system new ultrasound platform Flat detector capabilities in high-risk subtypes detection routine surgery Fast Track cycler & FastFinder software New SOMATOM Force MAMMOMAT R

  5. Slide 5: Atellica Solution shipments gaining speed

    Atellica Solution1) shipments gaining speed Ramp-up of analyzer shipments (cumulative) Comments • Targeting 7,000 analyzers by 2020 7,000+ • 80% to come out of own installed base • 20% to come from new customer wins • New customer wins currently well above 20% • Large contracts won across the world,

  6. Slide 6: Two attractive bolt-on acquisitions closed in FY2018

    Two attractive bolt-on acquisitions closed in FY2018 POC Epocal MDX Fast Track Diagnostics • Purchase price ~€170m (4x sales) • Purchase price ~€80m (~3.8x sales) • Siemens Healthineers now only vendor to offer a full solution in • One of the largest Molecular PCR test menu in the industry for blood

  7. Slide 7: Strong performance despite FX headwinds

    Strong performance despite FX headwinds Revenue (€m) Adj. Profit margin1) (€m) Adj. net income1) (€m) Comparable +4% Y-o-y Adj. EPS2) 0.34 0.42 growth +90 bps 3,396 3,226 +26% 16.5% 17.4% 428 341 Q2 FY2017 Q2 FY2018 Q2 FY2017 Q2 FY2018 Q2 FY2017 Q2 FY2018 • Overall comparable growth driven by • Adj.

  8. Slide 8: Strong Imaging business driving overall performance

    Strong Imaging business driving overall performance Imaging Diagnostics Advanced Therapies Comparable growth +6% +0% +2% Total revenue 1,997 1,050 1,946 970 377 352 (€m) Q2 FY2017 Q2 FY2018 Q2 FY2017 Q2 FY2018 Q2 FY2017 Q2 FY2018 Y-o-y +200 bps -10 bps -520 bps Adj. Profit margin1) 17.3% 19.3% 13.7%

  9. Slide 9: Capital structure post IPO as targeted

    Capital structure post IPO as targeted Summary balance sheet overview (as of March 31st 2018 in €m) Healthy capital structure post IPO (€bn) Cash and cash equivalents 196 Leverage (net debt / Receivables from Siemens Group (financial cash) 1,687 2.8x • Conversion of 1.5x EBITDA1)) intragroup liabili

  10. Slide 10: FY2018 guidance reaffirmed

    FY2018 guidance reaffirmed FY2017 (IFRS 15) FY2018E Comments on FY2018E Revenue (€m) 13,677 • Comparable revenue growth on a q-o-q basis can fluctuate significantly • Significant FX headwinds in FY2018E expected resulting in slightly decreasing Comparable growth (%) 3.8%1) 3-4% reported revenue Adj.

  11. Slide 11: Appendix

    Appendix Q2 FY2018 Analyst Call Page 10 | Unrestricted © Siemens Healthineers AG, 2018

  12. Slide 12: Provisions decreased as targeted due to extraordinary fundings in Germany

    Provisions decreased as targeted due to extraordinary fundings in Germany Q2 FY2018 Key financials – Pensions and similar obligations Q1 Q2 in €bn1) FY2015 FY2016 FY2017 FY2018 FY2018 Defined benefit obligation (DBO)2) (3.3) (4.6) (4.1) (3.5) (3.4) Fair value of plan assets2) 2.0 2.4 2.4 1.7 2.4 Pro

  13. Slide 13: Reported to adjusted net income reconciliation

    Reported to adjusted net income reconciliation Position (€m) Q2 FY2018 Q2 FY2017 Net income 308 305 therein: severance charges and IPO costs -103 -14 therein: PPA amortization -32 -37 therein: income tax effect1) 15 15 Adjusted net income2) 428 341 1) Calculated with a tax rate of 29.4% according to

  14. Slide 14: Reported to adjusted Profit reconciliation

    Reported to adjusted Profit reconciliation Q2 FY2018 Q2 FY2017 Advanced Advanced Healthineers Imaging Diagnostics Healthineers Imaging Diagnostics Position (€m) Therapies Therapies Profit 457 371 125 55 546 340 140 79 therein: severance charges -103 -5 -7 -1 -14 -6 -3 -1 and IPO costs Adjusted Profi

Siemens Healthineers — Q2 FY2018 Earnings Presentation on 6ix